Molecular Imaging and Contrast Agent Database adds 15 agents

Molecular Imaging and Contrast Agent Database (MICAD) has added 15 molecular imaging and contrast agents, totaling 913 agents in the MICAD database.

The new PET agents are:
  • anti-3-[18F]FACBC which targets L-type amino acid transporter;
  • [18F]FP-(+)-DTBZ ([18F]AV-133) which targets type 2 vesicular monoamine transporter (VMAT2);
  • [18F]7c which targets beta-amyloid;
  • [18F]PipISB which targets cannabinoid CB1 receptors;
  • [11C]DTBZ which targets type 2 vesicular monoamine transporter (VMAT2);
  • [11C]PipISB which targets cannabinoid CB1 receptors;
  • [64Cu]-AmBaSar-RGD which targets alpha v beta 3 integrin;
  • [64Cu]-AmBaSar which is non-targeted;
  • 68Ga-DOTA-Lys40-exendin-3 which targets glucagon-like peptide-1 receptor (GLP-1R);
  • 68Ga-DOTA-ZHER2:342-pep2 which targets epidermal growth factor receptor (HER2); and
  • 86Y-CHX-A''-DTPA-cetuximab which targets epidermal growth factor receptor (HER1).

The new SPECT agents are:
  • 111In-DTPA-Lys40-exendin-3 which targets glucagon-like peptide-1 receptor (GLP-1R); and
  • [99mTc]5 which targets carbonic anhydrase IX.

The new optical agent is:
  • IR-783 which targets lysosomes and mitochondria.

The new multimodality agent is: 
  • Cy5.5-CNP-Gd(III) which is non-targeted.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.